Meeting
2023 ASCO Annual Meeting
Bone biomarkers and subsequent survival in men with bone-metastatic hormone sensitive prostate cancer (HSPC): Results from the phase III SWOG S1216 trial of androgen deprivation +/- orteronel.
Authors
Primo N Lara Jr.
University of California Davis Comprehensive Cancer Center, Sacramento, CA
Primo N Lara Jr., Edward Mayerson , Erik Gertz , Catherine Tangen , Amir Goldkorn , Marta Van Loan , Maha H. A. Hussain , Shilpa Gupta , Jingsong Zhang , Mamta Parikh , Przemyslaw Twardowski , David I. Quinn , Michael Leo LeBlanc , Ian M Thompson Jr., Neeraj Agarwal
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Genitourinary Cancer—Prostate, Testicular, and Penile
Track
Genitourinary Cancer—Prostate, Testicular, and Penile
Sub Track
Prostate Cancer– Advanced/Castrate-Resistant
Clinical Trial Registration Number
NCT01809691
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 5048)
DOI
10.1200/JCO.2023.41.16_suppl.5048
Abstract #
5048
Poster Bd #
142
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Bone biomarkers and overall survival (OS) in men with advanced hormone-sensitive prostate cancer (HSPC): Results from SWOG S1216, a phase III trial of ADT +/- orteronel.
First Author: Primo "Lucky" N. Lara Jr.
Poster
2020 ASCO Virtual Scientific Program
Bone metabolism biomarkers (BMB) and progression-free survival (PFS) in men with metastatic hormone-sensitive prostate cancer (HSPC): SWOG S1216, a phase III trial of androgen deprivation therapy (ADT) with or without orteronel.
First Author: Primo Lara Jr.
Poster
2023 ASCO Annual Meeting
Baseline circulating tumor cell (CTC) count as a prognostic marker of overall survival (OS) in metastatic hormone sensitive prostate cancer (mHSPC): Results from SWOG S1216, a phase III randomized trial of androgen deprivation plus orteronel (cyp17 inhibitor) or bicalutamide.
First Author: Amir Goldkorn
Poster
2023 ASCO Annual Meeting
Prostate-specific antigen value at 3 & 7 months (PSA-3mo, PSA-7mo) and overall survival (OS) in metastatic hormone-sensitive prostate cancer (mHSPC) treated with androgen deprivation (ADT) with or without orteronel (SWOG S1216).
First Author: Mamta Parikh